These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11981102)

  • 1. Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups.
    Cohen M; Antman EM; Gurfinkel EP; Radley D;
    J Thromb Thrombolysis; 2001 Dec; 12(3):199-206. PubMed ID: 11981102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
    Antman EM; Cohen M; Bernink PJ; McCabe CH; Horacek T; Papuchis G; Mautner B; Corbalan R; Radley D; Braunwald E
    JAMA; 2000 Aug; 284(7):835-42. PubMed ID: 10938172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention.
    Fox KA; Antman EM; Cohen M; Bigonzi F;
    Am J Cardiol; 2002 Sep; 90(5):477-82. PubMed ID: 12208405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
    Santopinto J; Gurfinkel EP; Torres V; Marcos E; Bozovich GE; Mautner B; McCabe CH; Antman EM
    Am Heart J; 2001 Apr; 141(4):566-72. PubMed ID: 11275921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
    Cohen M
    Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.
    Antman EM; Cohen M; Radley D; McCabe C; Rush J; Premmereur J; Braunwald E
    Circulation; 1999 Oct; 100(15):1602-8. PubMed ID: 10517730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators.
    Antman EM
    Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S353-60. PubMed ID: 9628449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    Am J Cardiol; 1998 Sep; 82(5B):19L-24L. PubMed ID: 9737476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.
    Collet JP; Montalescot G; Fine E; Golmard JL; Dalby M; Choussat R; Ankri A; Dumaine R; Lesty C; Vignolles N; Thomas D
    J Am Coll Cardiol; 2003 Jan; 41(1):8-14. PubMed ID: 12570937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.
    Goodman SG; Cohen M; Bigonzi F; Gurfinkel EP; Radley DR; Le Iouer V; Fromell GJ; Demers C; Turpie AG; Califf RM; Fox KA; Langer A
    J Am Coll Cardiol; 2000 Sep; 36(3):693-8. PubMed ID: 10987586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
    Antman EM; McCabe CH; Gurfinkel EP; Turpie AG; Bernink PJ; Salein D; Bayes De Luna A; Fox K; Lablanche JM; Radley D; Premmereur J; Braunwald E
    Circulation; 1999 Oct; 100(15):1593-601. PubMed ID: 10517729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.
    Berkowitz SD; Stinnett S; Cohen M; Fromell GJ; Bigonzi F;
    Am J Cardiol; 2001 Dec; 88(11):1230-4. PubMed ID: 11728348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy.
    Goodman SG; Bozovich GE; Tan M; Dos Santos A; Gurfinkel EP; Cohen M; Langer A;
    Am Heart J; 2006 Apr; 151(4):791-7. PubMed ID: 16569535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enoxaparin: an update of its clinical use in the management of acute coronary syndromes.
    Ibbotson T; Goa KL
    Drugs; 2002; 62(9):1407-30. PubMed ID: 12076195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
    Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Danchin N; White HD; Santopinto J; Bigonzi F; Hecquet C; Vittori L;
    J Am Coll Cardiol; 2003 Oct; 42(8):1348-56. PubMed ID: 14563573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoxaparin. A review of its clinical potential in the management of coronary artery disease.
    Noble S; Spencer CM
    Drugs; 1998 Aug; 56(2):259-72. PubMed ID: 9711450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B.
    Turpie AG
    Can J Cardiol; 1998 Aug; 14 Suppl E():20E-23E. PubMed ID: 9779029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
    Cohen M; Théroux P; Borzak S; Frey MJ; White HD; Van Mieghem W; Senatore F; Lis J; Mukherjee R; Harris K; Bigonzi F;
    Am Heart J; 2002 Sep; 144(3):470-7. PubMed ID: 12228784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).
    Montalescot G; Bal-dit-Sollier C; Chibedi D; Collet JP; Soulat T; Dalby M; Choussat R; Cohen A; Slama M; Steg PG; Dubois-Randé JL; Metzger JP; Tarragano F; Guermonprez JL; Drouet L;
    Am J Cardiol; 2003 Apr; 91(8):925-30. PubMed ID: 12686329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.